About

iPerf is a medtech start-up created in 2021 to develop innovations in the field of cardiopulmonary assistance, thoracic and cardiovascular surgery.

iPerf has developed an innovative medical device to prevent serious and recurrent complications in patients receiving cardiopulmonary assistance via Extra Corporeal Membrane Oxygenation (ECMO)…

… and thus, improve patient survival. Indeed, the occurrence of a complication linked to the use of ECMO is associated with serious sequelae, but also with a significant increase in mortality in the days that follow.

iPerf is developing a device invented by Professor Pierre Mordant, a thoracic and vascular surgeon specialising in thoracic oncology and lung transplantation at Hôpital Bichat in Paris (AP-HP, Université Paris-Cité).

See the technologyRead the testimonials
A propos de iPerf
null

A vital indication

Rescuing patients in cardio-respiratory distress by installing devices to assist cardiac and respiratory functions enables many lives to be saved.
null

Current solutions

Current cannulas inserted into the femoral artery in the patient’s groin allow ECMO (Extra-Corporeal Membrane Oxygenation) to be connected and provide effective support for cardiac function, but to the detriment of blood supply to the leg, which can lead to severe complications.
null

A disruptive innovation

iPerf’s innovative cannula saves both the patient and his leg, because it is designed with an innovative dual-flow that distributes blood flow between the upper body and the leg, reproducing the physiological distribution.
Une qualité premium

Premium quality

Designed by a highly experienced practitioner, iPerf’s innovative cannula benefits from the latest advances in endovascular device design and materials.
Une équipe expérimentée

An experienced team

The iPerf team, now in charge of designing and developing the cannula corresponding to the system devised by Prof. Mordant, is multidisciplinary and covers the full range of skills needed to develop an innovative medical device.

CARE AND INNOVATE

Making ECMO safe – Improving patient survival.

At iPerf, we are convinced that the risks of permanent disability associated with the use of cardiopulmonary assistance via ECMO are unacceptable, for both patients and healthcare professionals.

iPerf is developing a disruptive solution that will make it possible to prevent these severe and frequent complications, and thus improve the survival of patients receiving such assistance.

iPerf was the brainchild of Professor Pierre Mordant, a thoracic and vascular surgeon, university professor and hospital practitioner at APHP and University Paris-Cité, who was confronted with this problem in the context of lung transplantation:
“I could no longer accept that a patient whose life had just been saved could leave hospital with a severe disability directly linked to the installation of cardiorespiratory assistance for the transplant”. Pr. Pierre Mordant.

The problem was clearly identified in all the centres using ECMO, and the source of these unacceptable risks was known… Pr. Mordant sought to find a solution and filed several patents.

iPerf is developing a new arterial ECMO cannula that allows practitioners to place the patient on cardiorespiratory assistance via ECMO, while eliminating the risk of ischaemia of the lower limb that could lead to the loss of the leg – with a potential benefit on the survival rate.

Caring

Demanding

Curiosity

Shared ambitions

TECHNOLOGY

iPerf cannula technology combines several patented innovations in a single device: an integrated dual irrigation system, a device positioning and a securing mechanism.

Optimal blood flow to the patient’s upper body, and at the same time to the leg.

Double flow to prevent serious and too-frequent complications in the lower limb.

The two circulation channels, known as “lumens”, enable optimal irrigation of the patient’s upper body and leg, from the femoral artery in the patient’s groin, at a single puncture point. This second flow to the leg helps prevent serious and too-frequent ischemic complications in the lower limb.

General principle

The iPerf cannula is a femoral arterial cannula designed for extracorporeal circulation (CEC and ECMO), providing dual flow:

  • The primary flow irrigates the upper body
  • The secondary flow irrigates the cannulated leg to reduce the risk of ischemic complications.

Technologie / Fonctionnement de l'ancre

Stabilizer functioning

A deployable positioning stabilizer has been designed to secure the position of the secondary outlet in the artery. After checking for reflux of the secondary lumen, the practitioner deploys the stabilizer and secures the position of the cannula in the artery.
Capture d'écran 2024-05-03 100017

Cannula design

The design and materials of the innovative iPerf cannula have been optimized for easy insertion into the femoral artery. The practitioner then uses the ergonomic handle to test the reflux of the (main and) secondary lumen(s), deploy the positioning stabilizer, connect the cannula to the ECMO circuit, and set up double perfusion of the patient’s body and the cannulated limb.

TESTIMONIALS

Pr. Guillaume Debaty

“Despite a reperfusion catheter, 10 to 20% of patients undergoing ECMO will develop an ischemic complication of the cannulated limb, the consequences of which can be dramatic…/… The innovation provides a highly relevant response to the difficulties involved in designing a dual-perfusion cannula: separation of the two flows as soon as they enter the cannula, making it possible to manage the ratios of main and secondary flows, and a mechanism for securing the exit point of the accessory flow. Simulation tests give good results, and animal trials confirm them…. “

Pr. Matthieu Schmidt

“…Despite our experience over several years, leg ischemia remains a major problem in ECMO-VA cannulation, and no satisfactory solution has yet been found to reduce this risk…/… The prototype proposed by the iPerf seems to be very promising and responds to a concrete problem…”

Pr. Eloi Marijon

“Circulatory assistance is a key strategy in the management of refractory cardiac arrest and cardiogenic shock. The risk of local ischemia in the lower limb is known and documented: any cannula that can limit this risk is welcome.”

Dr. Sylvain Beurtheret

“I became very interested in ECMO …/… this technique presents the paradox of being increasingly used in view of its efficacy, despite serious and recurrent complications that remain unaddressed today …/… iPerf has developed a double-lumen ECMO-VA cannula enabling integrated reperfusion of the cannulated lower limb. By studying successive prototypes and following the evolution of the project, I have been able to confirm my initial analysis: iPerf’s cannula appears to be a perfectly adapted solution for reducing ECMO-related complications.”

Dr. Nicolas Valerio

“ECMO, already widely used within hospitals to treat cardiac failure, is tending to develop outside hospitals, since it has been shown to triple the chances of survival for patients in refractory cardiac arrest occurring outside a hospital. However, this technique still all too frequently (10 to 20% of cases) induces severe ischemia of the lower limb, which is prognostic and may lead to amputation.”

TEAM

The founders

Prof. Pierre MORDANT

MD, PhD, Hôpital Bichat, APHP, Paris

Professor Mordant is a renowned surgeon in the fields of thoracic and vascular surgery, specializing in lung transplantation. He is the inventor of the technology developed by iPerf.

He is heavily involved in R&D, clinical strategy and the development of a network of practitioners and opinion leaders, to ensure that his innovation, which brings considerable patient benefit, successfully passes all stages of development.

Linkedin

Maya BERTRON

CEO of iPerf

Maya has over 15 years’ experience in Mergers & Acquisitions, Private Equity and listed market capital transactions (public offerings, IPOs, particularly of biotech and medtech companies). He has surrounded himself with experienced collaborators (engineering, regulatory and quality, clinical) and high-level partners, to form a multidisciplinary team capable of rapidly bringing iPerf’s innovation to market.

Linkedin

The team

Caroline Rosset

Regulatory Affairs and Quality Assurance Manager

Caroline holds a Master 2 in Pharmaceutical Biotechnology and Innovative Therapies from the Université de Paris-Saclay.

Linkedin
Ines Ferreira

R&D Engineer

Inês graduated from Université de Technologie de Compiègne with a degree in biological engineering, specializing in biomechanics and biomaterials.

Linkedin
Anne Laplante

R&D Engineer and Technical Manager

Anne holds a Master’s degree in BioMedical Engineering and Design from the Ecole des Mines de St Etienne.

Linkedin
Kevin Breut

CTO

Kevin holds two engineering degrees, one from the École nationale supérieure d’arts et métiers ParisTech and the other from the University of Karslruhe.

Linkedin

Scientific Advisory Board

Dr. Jonathan Yeung

Thoracic Surgeon, Toronto General Hospital, Specialized in lung transplant

Dr. Demetris Yannopolous

M.D. Professor of Medicine, University of Minnesota​, Pioneer of ECMO-based resuscitation in the USA in refractory cardiac arrest outside of hospital​

Pr. John Fraser

Head of Intensive Care, Brisbane, Founder and CMO of De Motu Cordis, Past Chairman of Asia-Pacific ELSO

Pr. Guillaume Debaty

Professor of Emergency Medicine, Head of the SAMU Isère Department, Grenoble University Hospital

Dr. Nicolas Valerio

Vascular Surgeon, Hôpital Saint Joseph, Marseille

Pr. Matthieu Schmidt

Resuscitator, MD PhD at Pitié Salpêtrière Hospital, Paris

Pr. Eloi Marijon

MD PhD, Cardiologist Head of the Rhythmology Unit at Hôpital Européen Georges-Pompidou (HEGP), Paris

Dr. Sylvain Beurtheret

Cardiovascular Surgeon, Hôpital Saint Joseph, Marseille

Strategic Board Members

Julien Sicluna

Strategic Advisor

Personal blog / website
Fabien Dherbassy

Founder of INESO

Linkedin
Nathalie Pavia

Founder of ALBERT & CO

Linkedin
François Sebes

Former Chairman CENTUM ADETEL GROUP

Linkedin
Fabrice Romano

Founder of Keranova and EyeTechCare

Linkedin

PARTNERS

BPI France
Bpifrance finances businesses from the seed phase to transfer to stock exchange listing, through loans, guarantees and equity.
Assistance publique
AP-HP is the largest university hospital centre in Europe and is known worldwide. As a public health institution, AP-HP pursues 3 main missions: care, training, research and innovate.
SEGULA Technologies is an engineering group of French origin, present in 30 countries, with 140 locations and nearly 13,000 employees. SEGULA carries out large-scale projects, ranging from studies to industrialization and production.
Veranex Preclinical Services, France provides high quality services for complex preclinical studies in large models and has expertise in cardiovascular research, a space that demands a high technical standard.
Since 1920, Laurent & Charras has been supporting innovative project holders and companies with all industrial property issues: patents, trademarks, designs and models, partnerships, etc.
iPerf’s office are hosted by Le Village by CA, in La Grande Maison (Champagne au Mont d’Or).
Banking partner
Banking partner
Banking partner
Banking partner

NEWS

Sep292026

AATS poster

Iperf is delighted to present the results of its first clinical trial at the AATS Mechanical Support and Thoracic Transplantation Summit. You can download the poster here.

Download article
Sep242026

Press Release – FIH Clinical investigation

iPerf concludes promising clinical trial of novel dual-lumen femoral arterial cannula for cardiopulmonary support No device-related serious adverse events were reported during the first-in-human trial of 15 patients receiving cardiopulmonary support NIRS monitoring showed maintained tissue oxygenation in the cannulated limb, with no sign of impaired distal perfusion Full results will be presented at the AATS Mechanical Support and…

See article
Apr302026

Press Release – First patient

iPerf enrolls first patient in clinical trial of innovative dual-flow femoral arterial cannula for cardiopulmonary support First-ever dual-flow device designed to prevent severe vascular complications and amputations when performing critical heart and lung life-support techniques (ECMO and CPB) Innovation driven by company co-founder, thoracic and vascular surgeon Professor Pierre Mordant, with his 15+ years’ expertise…

See article

Funding

iPerf announces that €7 million has been successfully raised in seed funding over the period 2021-2023. This round has enabled iPerf to build a strong team, validate the performance of its device, prepare its first clinical study and its access to the US market (preparation in progress).

Download article

Publication

The iPerf team led by prof. Pierre Mordant, MD PhD at Hôpital Bichat in Paris has published an article in the Journal of Clinical Medicine entitled: “Preventing Acute Limb ischemia during VA-ECMO – In Silico Analysis of Physical Parameters Associated with Lower Limb Perfusion”.

Download article
May32024

Publication

American College of Cardiology’s 75rd Annual Scientific Session: Dr Sylvain Beurtheret and Pr Pierre Mordant, members of iPerf’s Scientific Advisory Board, presented the results of their research on: “ Adverse Impact of Vascular Complications in Patients with Cardiogenic Shock and Extra Corporeal Membrane Oxygenation “. This real-life study analyzes in detail the vascular complications of…

See article
May32024

Clinical trial

Now that the design of the innovative cannula has been completed, and validation tests on the prototypes carried out, iPerf has ordered its first pre-series of cannulas for the Clinical Study and First In Human.

See article

CONTACT

If you would like to contact us, join our teams, learn more about our system, or participate in the IPERF adventure as an Investor, partner, subcontractor, etc., send us a message using the form below. Thank you in advance!